Inactivation/Attenuation TRIZ Cases

Hydrophobic interaction chromatography resolves large virion loading issues by reducing DNA and protein contamination while maintaining biological activity.

Extracting the CPMV 5' UTR resolves biocontainment risks while enabling high-level transient protein expression.

Protectant scavengers neutralize reactive species during UV-C exposure, preventing protein degradation while ensuring effective viral inactivation.

Placing transgenes between viral transcription units resolves the contradiction between replicative potential and therapeutic gene expression.

Deleting the S1 gene removes broad cellular tropism, eliminating cytopathic effects on normal cells and enabling selective lysis of cancer cells.

Specific genomic deletions create attenuated vaccinia strains that replicate in human cells, resolving the contradiction between vaccine safety and potency.

Combining low pH with sugar-based detergents accelerates viral inactivation, preventing antibody aggregation during continuous manufacturing.

Ultraviolet radiation inactivates pathogens while preserving antigenic characteristics, resolving the trade-off between safety and immune recognition.

Optimized 80 nm pore size nanofilters separate enveloped and non-enveloped viruses from Factor VII without mechanical degradation.

VP2 capsid mutations enable single-dose vaccination independent of maternal antibodies, closing the susceptibility window.